RARE Institutional Ownership

ULTRAGENYX PHARMACEUTICAL IN

Latest close $24.97 as of Aug 5, 2026

Create account to watch
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices. Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes. Filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro. The overall institutional consensus preview remains public. Compare plans.
Cross-institution intelligence

Institutional Research

Each institution is compared with its own prior filing, then the latest institution-level directions are compared for breadth.

Latest filing Jul 31, 2026
Public consensus preview Mixed positioning 50/100 institutional research score
6 tracked institutions Latest filing Jul 31, 2026

No institution has two comparable Schedule 13 observations yet.

Accumulating0
Unchanged0
Reducing0
Exited0

The overall consensus is public. Detailed holder comparisons, breadth history, ownership charts, and filing-specific signal analysis remain part of Investor and Pro research.

Price context

52-week position is market context and does not change the institutional consensus score.

52-week low$18.29 52-week high$42.37
Latest close $24.97 27.7% through the range

Tracked institutions

Public holder names and filing freshness. Detailed institution-by-institution analysis is locked.

Latest observation Jun 30, 2026
Vanguard Capital Management Jul 31, 2026 filed
BlackRock Jul 30, 2026 filed
State Street May 12, 2026 filed
Vanguard Group Mar 27, 2026 filed
Fidelity / FMR Feb 5, 2026 filed
Detailed institutional research

See what is driving the consensus.

Unlock holder-by-holder changes, ownership history, breadth by period, disclosure timing, and filing-specific signal analysis.

Create free account Compare Investor and Pro

A free account adds watchlists and reveals tracker research gauges. Investor or Pro unlocks the detailed research above.

Beneficial ownership filing history

Showing 3 of 7 parsed filing(s) · 4 older require more history access
Holder Observed / filed Reported change Shares Ownership Observation Filing Latest
Vanguard Capital Management CIK0002100119 Jun 30, 2026 observed Jul 31, 2026 filed · 31d Initial Schedule 13G Initial Schedule 13G 5.1M 12.00% $33.39 $24.91 $24.97
BlackRock CIK0002012383 Jun 30, 2026 observed Jul 30, 2026 filed · 30d Schedule 13G amendment Earliest Schedule 13G amendment found 8.1M 12.00% $33.39 $26.04 $24.97
State Street CIK0000093751 Mar 31, 2026 observed May 12, 2026 filed · 42d Initial Schedule 13G Initial Schedule 13G 5.0M 12.00% $20.95 $26.84 $24.97
Explore more institutional activity

Related research

Crawlable links to other securities with similar institutional consensus or recent multi-institution accumulation.

Similar research strength

TTAN SERVICETITAN INC-A 50/100 Mixed positioning SITC SITE CENTERS CORP 50/100 Mixed positioning SYNA SYNAPTICS Inc 50/100 Mixed positioning TRU TRANSUNION 50/100 Mixed positioning

Recent multi-institution accumulation

TVTX TRAVERE THERAPEUTICS INC 2 accumulating Aug 6, 2026 PCVX VAXCYTE INC 2 accumulating Aug 6, 2026 VVX V2X INC 2 accumulating Aug 6, 2026 VSEC VSE CORP 3 accumulating Jul 31, 2026